IBDEI3BD ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1205,0)
 ;;=EYE DISORDERS^27^107
 ;;^UTILITY(U,$J,358.4,1206,0)
 ;;=EYE INJURY^28^107
 ;;^UTILITY(U,$J,358.4,1207,0)
 ;;=GASTROENTEROLOGY^29^107
 ;;^UTILITY(U,$J,358.4,1208,0)
 ;;=GU/RENAL^30^107
 ;;^UTILITY(U,$J,358.4,1209,0)
 ;;=HEADACHE^31^107
 ;;^UTILITY(U,$J,358.4,1210,0)
 ;;=HEART VALVE DISEASE^32^107
 ;;^UTILITY(U,$J,358.4,1211,0)
 ;;=HEMATOLOGY/ONCOLOGY^33^107
 ;;^UTILITY(U,$J,358.4,1212,0)
 ;;=HISTORY OF ILLNESS^34^107
 ;;^UTILITY(U,$J,358.4,1213,0)
 ;;=INFECTIOUS DISEASE^35^107
 ;;^UTILITY(U,$J,358.4,1214,0)
 ;;=LIVER DISEASE^36^107
 ;;^UTILITY(U,$J,358.4,1215,0)
 ;;=MENTAL HEALTH^38^107
 ;;^UTILITY(U,$J,358.4,1216,0)
 ;;=MOVEMENT DISORDERS^39^107
 ;;^UTILITY(U,$J,358.4,1217,0)
 ;;=MUSCULOSKELETAL^40^107
 ;;^UTILITY(U,$J,358.4,1218,0)
 ;;=NEUROLOGY^41^107
 ;;^UTILITY(U,$J,358.4,1219,0)
 ;;=PAIN^42^107
 ;;^UTILITY(U,$J,358.4,1220,0)
 ;;=PREVENTIVE HEALTH^43^107
 ;;^UTILITY(U,$J,358.4,1221,0)
 ;;=PULMONARY^44^107
 ;;^UTILITY(U,$J,358.4,1222,0)
 ;;=SEXUAL TRAUMA^45^107
 ;;^UTILITY(U,$J,358.4,1223,0)
 ;;=SIGNS,SYMPTOMS,CONDITIONS^46^107
 ;;^UTILITY(U,$J,358.4,1224,0)
 ;;=SPRAIN/STRAIN-INITIAL ENCOUNTER^47^107
 ;;^UTILITY(U,$J,358.4,1225,0)
 ;;=SUBSTANCE DISORDERS^48^107
 ;;^UTILITY(U,$J,358.4,1226,0)
 ;;=VARICOSE VEINS^50^107
 ;;^UTILITY(U,$J,358.4,1227,0)
 ;;=WOMEN'S HEALTH^51^107
 ;;^UTILITY(U,$J,358.4,1228,0)
 ;;=WOUNDS-INITIAL ENCOUNTER^52^107
 ;;^UTILITY(U,$J,358.4,1229,0)
 ;;=COMA^20^107
 ;;^UTILITY(U,$J,358.4,1230,0)
 ;;=CAUSES OF INJURY^19^107
 ;;^UTILITY(U,$J,358.4,1231,0)
 ;;=DEMENTIA^21^107
 ;;^UTILITY(U,$J,358.4,1232,0)
 ;;=LONG TERM CURRENT DRUG THERAPY^37^107
 ;;^UTILITY(U,$J,358.4,1233,0)
 ;;=ACQUIRED ABSENCE OF BODY PART(S)^2^107
 ;;^UTILITY(U,$J,358.4,1234,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^49^107
 ;;^UTILITY(U,$J,358.4,1235,0)
 ;;=ACSC ACUTE KIDNEY FAILURE^3^107
 ;;^UTILITY(U,$J,358.4,1236,0)
 ;;=ACSC ANGINA^4^107
 ;;^UTILITY(U,$J,358.4,1237,0)
 ;;=ACSC ASTHMA/BRONCHITIS/COPD^5^107
 ;;^UTILITY(U,$J,358.4,1238,0)
 ;;=ACSC CHF^6^107
 ;;^UTILITY(U,$J,358.4,1239,0)
 ;;=ACSC DEHYDRATION^7^107
 ;;^UTILITY(U,$J,358.4,1240,0)
 ;;=ACSC DIABETES TYPE 1^8^107
 ;;^UTILITY(U,$J,358.4,1241,0)
 ;;=ACSC DIABETES TYPE 2^9^107
 ;;^UTILITY(U,$J,358.4,1242,0)
 ;;=ACSC HYPERTENSION^10^107
 ;;^UTILITY(U,$J,358.4,1243,0)
 ;;=ACSC INFECTIOUS GASTROENTERITIS^11^107
 ;;^UTILITY(U,$J,358.4,1244,0)
 ;;=ACSC PNEUMONIA^12^107
 ;;^UTILITY(U,$J,358.4,1245,0)
 ;;=ACSC UTI^13^107
 ;;^UTILITY(U,$J,358.4,1246,0)
 ;;=ACSC VIRAL ENTERITIS^14^107
 ;;^UTILITY(U,$J,358.4,1247,0)
 ;;=E-CIG/VAPE LUNG INJURY^23^107
 ;;^UTILITY(U,$J,358.4,1248,0)
 ;;=OTHER CODES^12^108
 ;;^UTILITY(U,$J,358.4,1249,0)
 ;;=MENTAL HEALTH INTAKE CODES^11^108
 ;;^UTILITY(U,$J,358.4,1250,0)
 ;;=OTHER PSYCHOTHERAPY^13^108
 ;;^UTILITY(U,$J,358.4,1251,0)
 ;;=BIOFEEDBACK^3^108
 ;;^UTILITY(U,$J,358.4,1252,0)
 ;;=CASE MANAGEMENT^4^108
 ;;^UTILITY(U,$J,358.4,1253,0)
 ;;=INPT OR OTPT PSYTX W/O E&M^9^108
 ;;^UTILITY(U,$J,358.4,1254,0)
 ;;=INTERACTIVE COMPLEXITY ADD-ON^10^108
 ;;^UTILITY(U,$J,358.4,1255,0)
 ;;=OTPT PSYTX W E&M ADD-ON^14^108
 ;;^UTILITY(U,$J,358.4,1256,0)
 ;;=PSYCHOTHERAPY FOR CRISIS^19^108
 ;;^UTILITY(U,$J,358.4,1257,0)
 ;;=PROLONGED SERVICES ADD-ON^18^108
 ;;^UTILITY(U,$J,358.4,1258,0)
 ;;=INJECTIONS^8^108
 ;;^UTILITY(U,$J,358.4,1259,0)
 ;;=PREVENTIVE MEDICINE COUNSELING^15^108
 ;;^UTILITY(U,$J,358.4,1260,0)
 ;;=PREVENTIVE MEDICINE-EST PT^16^108
